• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.

作者信息

Guerineau Hippolyte, Cayuela Jean-Michel, Dulucq Stéphanie, Tran Quang Violaine, Tarfi Sihem, Gricourt Guillaume, Barathon Quentin, Joy Corine, Wagner-Ballon Orianne, Morisset Stéphane, Nicolini Frank-Emmanuel, Brunet Erika, Maury Sébastien, Roy Lydia, Etienne Gabriel, Réa Delphine, Sloma Ivan

机构信息

Hematology and Immunology Department, AP-HP, Henri Mondor University Hospital, Creteil, France.

AP-HP, Laboratory of Hematology, Saint-Louis University Hospital and EA3518, University, Paris, France.

出版信息

Am J Hematol. 2025 Mar;100(3):507-510. doi: 10.1002/ajh.27553. Epub 2024 Dec 10.

DOI:10.1002/ajh.27553
PMID:39654506
Abstract
摘要

相似文献

1
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.诊断时表观遗传调节因子的突变是慢性髓性白血病酪氨酸激酶抑制剂治疗失败的独立预测因素：来自RESIDIAG研究的报告
Am J Hematol. 2025 Mar;100(3):507-510. doi: 10.1002/ajh.27553. Epub 2024 Dec 10.
2
A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation.1例伴有ASXL1突变的酪氨酸激酶抑制剂耐药慢性期慢性髓性白血病病例
Case Rep Oncol. 2020 Apr 22;13(1):449-455. doi: 10.1159/000506452. eCollection 2020 Jan-Apr.
3
Case Report: , , and mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase.病例报告：酪氨酸激酶非依赖性耐药慢性髓性白血病进展为慢性粒单核细胞白血病样加速期时的 、 和 突变
Front Oncol. 2023 Sep 7;13:1217153. doi: 10.3389/fonc.2023.1217153. eCollection 2023.
4
Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.外显子组测序显示，DNMT3A和ASXL1变异与酪氨酸激酶抑制剂治疗后慢性髓性白血病的进展相关。
Leuk Res. 2017 Aug;59:142-148. doi: 10.1016/j.leukres.2017.06.009. Epub 2017 Jun 16.
5
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.ASXL1 突变可预测慢性髓性白血病患者对尼罗替尼治疗的分子反应较差。
Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28.
6
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.表观遗传修饰物中的体细胞变异可预测对伊马替尼的耐药，但不能预测对第二代酪氨酸激酶抑制剂的耐药。
Haematologica. 2019 Dec;104(12):2400-2409. doi: 10.3324/haematol.2018.200220. Epub 2019 May 9.
7
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.ASXL1 突变对慢性期慢性髓性白血病的预后影响。
Blood Cancer J. 2022 Oct 28;12(10):144. doi: 10.1038/s41408-022-00742-1.
8
CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway.携带突变型ASXL1的慢性粒细胞白血病通过上调ALOX5-BLTR信号通路显示出对酪氨酸激酶抑制剂治疗的敏感性降低。
Cancer Sci. 2025 Apr;116(4):1115-1125. doi: 10.1111/cas.70007. Epub 2025 Feb 4.
9
Secondary chronic myeloid leukemia in a patient with CALR and ASXL1-mutated primary myelofibrosis.继发于伴有 CALR 和 ASXL1 突变的原发性骨髓纤维化的慢性髓性白血病。
Int J Hematol. 2022 Sep;116(3):442-445. doi: 10.1007/s12185-022-03331-x. Epub 2022 Apr 16.
10
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.LYN 和 PTEN 基因在慢性髓性白血病中的表达及其在治疗策略中的重要性。
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3.

引用本文的文献

1
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.评估欧洲型队列中酪氨酸激酶抑制剂治疗失败的预测模型：迈向针对特定人群的工具的一步。
Leukemia. 2025 Aug 1. doi: 10.1038/s41375-025-02703-6.
2
Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia.真性红细胞增多症、慢性粒单核细胞白血病和慢性髓性白血病的亚克隆出现。
Ann Hematol. 2025 May 24. doi: 10.1007/s00277-025-06417-8.
3
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers.
慢性髓系白血病的生物学：新见解与生物标志物概述
Front Oncol. 2025 May 8;15:1546813. doi: 10.3389/fonc.2025.1546813. eCollection 2025.
4
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.与儿童、成人以及BCR::ABL1阳性急性淋巴细胞白血病相比，慢性髓性白血病青少年和年轻成人的体细胞突变与预后
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02609-3.